Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CERo Therapeutics Holdings, Inc. Common Stock (CERO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CERO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -31.77% | Avg. Invested days 102 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.79M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 774240 | Beta -0.44 | 52 Weeks Range 0.65 - 223.00 | Updated Date 02/14/2025 |
52 Weeks Range 0.65 - 223.00 | Updated Date 02/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.28% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12726648 | Price to Sales(TTM) - |
Enterprise Value 12726648 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 51353500 | Shares Floating 46458656 |
Shares Outstanding 51353500 | Shares Floating 46458656 | ||
Percent Insiders 12.54 | Percent Institutions 9.05 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CERo Therapeutics Holdings, Inc. Common Stock
Company Overview
History and Background
CERo Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing novel cell therapies for the treatment of cancer. The company's history involves preclinical research, clinical trials, and development of its cell therapy platforms. Details on founding year and early milestones are limited in public domain.
Core Business Areas
- Cell Therapy Development: Focuses on developing off-the-shelf cell therapies for cancer treatment, utilizing its proprietary technologies.
Leadership and Structure
Information regarding the specific leadership team and organizational structure is not readily available in detail. Publicly traded companies are required to disclose key leadership. However details on the complete org chart will require extensive private research.
Top Products and Market Share
Key Offerings
- CER-123: CER-123 is CERo Therapeutics' lead product candidate, an allogeneic T cell therapy targeting multiple myeloma. Clinical trials are ongoing. Market share data is unavailable as the product is still in development. Competitors include companies developing CAR-T therapies such as Johnson & Johnson and Bristol Myers Squibb.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and personalized medicine. Significant unmet needs in cancer treatment are fueling innovation.
Positioning
CERo Therapeutics is positioned as a developer of off-the-shelf cell therapies, offering a potential advantage over patient-specific CAR-T therapies in terms of cost and accessibility.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is estimated to be in the tens of billions of dollars. CERo Therapeutics aims to capture a portion of this market with its allogeneic cell therapy platform.
Upturn SWOT Analysis
Strengths
- Novel allogeneic cell therapy platform
- Potential for off-the-shelf cancer treatment
- Focus on multiple myeloma
Weaknesses
- Clinical stage company with no approved products
- High R&D expenses
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion to other cancer indications
- Advancements in cell therapy manufacturing technologies
Threats
- Clinical trial failures
- Competition from established cell therapy companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- GILD
Competitive Landscape
CERo Therapeutics faces intense competition from established pharmaceutical companies with approved cell therapies. Its competitive advantage lies in its allogeneic approach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable since it is still in the clinical trial stage.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals.
Recent Initiatives: CERo Therapeutics is focused on advancing its CER-123 program and exploring other applications of its cell therapy platform.
Summary
CERo Therapeutics is a clinical-stage biotech firm focused on allogeneic cell therapies for cancer. Its success hinges on the outcomes of its clinical trials, particularly for CER-123. It is in a very competitive market. Financial metrics require close monitoring due to high R&D expenses. Further, it will need to secure partnerships for long term sustenance.
Similar Companies
- JNJ
- BMY
- GILD
- BLUE
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2024-02-15 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.